









SPONSOR 主办 浙江大学医学院附属第二医院|美国加州大学洛杉矶分校医学院

> COLLABORATOR 协办 海南博鳌医学创新研究院

2018.09.18-20 HANGZHOU·CHINA|中国・杭州

杭州凯悦酒店B2层大宴会厅II BALLROOM II, FLOOR B2, HYATT REGENCY HANGZHOU





Steven R. Houser

Senior Associate Dean, Research Vera J. Goodfriend Endowed Chair, Cardiovascular Research Chair and Professor, Physiology Director, Cardiovascular Research Center (CVRC) Professor, Medicine Temple University Lewis Katz School of Medicine Past President of AHA 2017-2018

Dr. Houser is an internationally respected cardiovascular researcher who has been a Temple faculty member for more than three decades. His research group has helped define many fundamental features of the normal cardiac myocyte as well as identified defective molecular and cellular processes that produce abnormal cardiac myocyte function in cardiovascular disease. This group was awarded a five-year, \$11.6 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health in 2012 to develop new approaches to prevent, slow or reverse damage to the heart after a heart attack. He has a long association with the American Heart Association, serving as a board member, Chair of the Research Committee, and President of the Southeastern Pennsylvania Affiliate. He has also served on a number of national AHA committees. He is Past President of AHA 2017-2018.



Junbo Ge

Academician, Chinese Academy of Sciences Chief, Cardiology Department of Zhongshan Hospital Chief, Shanghai Cardiovascular Clinical Center Chairman, Shanghai Institute of Cardiovascular Diseases Fudan University

President, Chinese Society of Cardiology

Dr. Ge dedicates to the optimization and innovation of diagnosis and treatment strategy for coronary artery disease and made extraordinary achievements in intravascular ultrasound (IVUS). His research areas also include development of novel coronary stents, treatment strategy optimization of complex CAD and stem cell therapy. Dr. Ge has been responsible for over 20 scientific research projects supported by the government, Furthermore, a total of over 300 papers published by Prof. Ge have been included by SCI-E (as the first author or the corresponding author). He was awarded Scholars of the Yangtse River; Elite of science and technology; National Labor Medal; Tan Jiazhen prize in life sciences; the national "Bethune" Medal, etc.



Joseph A. Hill

Professor, Internal Medicine and Molecular Biology James T. Willerson, M.D. Distinguished Chair in Cardiovascular Diseases Frank M. Ryburn, Jr, Chair in Heart Research Chief, Division of Cardiology Director, Harry S. Moss Heart Center University of Texas Southwestern Medical Center

Joseph Hill is Professor of Internal Medicine and Molecular Biology, Chief of Cardiology at UT Southwestern Medical Center, and Director of the Harry S. Moss Heart Center. His research group strives to decipher mechanisms of structural, functional, metabolic, and electrical remodeling in heart disease with an eye toward therapeutic intervention. He has received numerous recognitions and awards, including election to the Association of American Professors; he recently served as President of the Association of University Cardiologists and chair of the Academic Council of the American College of Cardiology. He received the 2018 Research Achievement Award from the International Society for Heart Research. Presently, he serves as Editor-in-Chief of Circulation. Dr. Hill maintains an active clinical practice focusing on general cardiology, heart failure, and hypertension.



Ross Solaro

Professor and Head, Department of Physiology & Biophysics University of Illinois College of Medicine Editor in Chief, JMCC

Dr. Solaro is interested in the fundamental mechanisms responsible for regulation of the molecular motors of heart muscle cells. These motors are housed in myofilaments responsible for shortening of cardiac muscle cells. His focus is on the molecular switch that turns on the motor. His experiments address the following question: What events signal switch function and how is the switch modulated by myofilament structure, chemistry, mechanical state and drugs? He approached this question at several levels of organization by integrating information derived from techniques using the disciplines of biophysics, biochemistry as well as molecular, structural and cellular biology. An important endpoint and success of his approaches has been the development of new drugs for use in the treatment of heart failure.

- Head, Institutes of Biomedical Sciences, Institute for Pan vascular Medical Research



Jay Zhang

Professor, Medicine Professor and Chair, Department of Biomedical Engineering T. Michael and Gillian Goodrich Endowed Chair, Engineering Leadership University of Alabama at Birmingham

Dr. Zhang went to UAB in October 2015 after he was chosen in a national search to lead the UAB BME department from the University of Minnesota Medical School, where he was the Engdahl Family Foundation Chair in Cardiovascular Regenerative Therapies, in addition to being a tenured professor of medicine, of biomedical engineering, of electrical engineering, and computer engineering. His research interests include tissue engineering, myocardial energetics in hearts with postinfarction left-ventricle remodeling, heart failure, biomaterials, and stem cells for cardiac repair. He is currently the principal investigator of three R01 NIH grants in the fields of myocardial bioenergetics, biomaterials, and stem cells for cardiac repair, and an NIH U01 grant for the NHLBI Progenitor Cell Translational Consortium (PCTC) on cardiovascular tissue engineering, which continuous through 2022.



Dongfeng Gu

Academician, Chinese Academy of Sciences; Deputy Director, National Center for Cardiovascular Diseases, China; Vice President of Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Professor, Chiar of Department of Epidemiology;

Dr. Gu has led large observational and interventional studies in both the genomic fields and epidemiology that have explored the risk factors associated with hypertension, coronary artery disease and what impacted prevention of cardiovascular diseases (CVD) in populations. He is a council member of the International Society of Cardiovascular Epidemiology and Prevention, and the president of Chinese Society of Preventive Cardiology. Dr. Gu is a Deputy Chief Editor for Chronic Diseases and Translational Medicine, and served on the editorial boards of the Journal of Hypertension, the Human Genetics. Publications include over 280 articles in peer-reviewed international medical journals such as New Engl J Med, Lancet, JAMA and Nat Genet.



Elizabeth Murphy

Senior Investigator, Laboratory of Cardiac Physiology National Heart, Lung, and Blood Institute NIH President, ISHR

Dr. Murphy's laboratory studies the molecular mechanisms involved in cardiac cell death, as well as the mechanisms that protect the heart against damage. The knowledge gained from these studies may help identify novel therapies to reduce cardiac injury during ischemia and reperfusion. The current dogma suggests that calcium overload and reactive oxygen species generated during ischemia and heart failure lead to activation of a mitochondrial pore (mPTP) which initiates cell death. As part of her overall interest in cardioprotection, Dr. Murphy has a specific interest understanding the natural cardioprotection that exists among pre-menopausal females. Her laboratory is currently examining whether selective estrogen receptor modulators (SERMs), can mediate cardioprotection in a similar fashion to endogenous estrogen, opening up a possible therapeutic avenue to reduce heart attack damage in women.



Ruiping Xiao

Professor Director of IMM/PKU Principal Investigator, Laboratory of Signal Transduction Peking University

Dr. Xiao is the Director of the Institute of Molecular of Medicine (IMM) at Peking University and the Peking University Chair Professor. Dr. Xiao's research has been focused on cardiovascular and metabolic diseases, with a major emphasis on a translational approach to take bench discoveries into clinically relevant situations. Ongoing research directions include signaling pathways involved in metabolic syndrome and associated cardiovascular complications. Currently, Dr. Xiao serves as a Council Member of the International Society of Heart Research and an Associate Editor of the New England Journal of Medicine and an Editorial Board Member of multiple international top journals.



Charles Steenbergen Jr

Professor, Pathology and Director, Cardiovascular Pathology Johns Hopkins University

Dr. Charles Steenbergen is a professor of pathology at the Johns Hopkins University School of Medicine. He specializes in cardiovascular and transplant pathology. His research focuses on mechanisms of ischemic heart disease, and in particular, endogenous mechanisms that can be activated to protect the heart during a subsequent episode of ischemia and reperfusion. He is interested in identifying signal transduction pathways that are involved in cardioprotection, and understanding how these signaling pathways confer their protective effect. His lab studies the mechanisms of injury involving ionic dysequilibrium, and has used magnetic resonance spectroscopic techniques to monitor ion concentrations in intact hearts during ischemia and reperfusion. Since infarct size is a major determinant of clinical outcome in patients with ischemic heart disease, the lab hopes that better understanding of these protective mechanisms will lead to the development of better therapies for patients with coronary artery disease and patients undergoing heart surgery.



Gerald W. Dorn, II

Philip & Sima K Needleman Professor, Internal Medicine Pharmacogenomics Washington University in St. Louis

Dr. Dorn's lab studies the heart as a model for understanding molecular mechanisms that drive cell growth, phenotypic reprogramming, and death. The team examines how altered genetic programming leading to pathological cardiomyocyte growth or programmed cell death contributes to diseases such as cardiac hypertrophy, hypertrophic and dilated cardiomyopathy, and heart failure. He discovered fundamental mechanisms regulating mitochondrial homeostasis, programmed elimination, and metabolic remodeling in cardiac and neurological disease. His early studies showed that neurohormonal signaling promotes myocardial transcription of mitochondrial Bcl2 family death proteins were among the first to mechanistically link cardiac hypertrophy with apoptotic heart failure. He recently established that mitofusins transition between fusion-constrained and fusion-permissive conformations.



Yibin Wang

Professor, Molecular Medicine Chair, Cardiovascular Theme Vice Chair, Research in the Department of Anesthesiology and Perioperative Medicine Director, the Division of Molecular Medicine in the Department of Anesthesiology and Perioperative Medicine UCLA David Geffen School of Medicine

Dr. Wang's research mainly focuses on genetic and molecular mechanisms of heart failure and metabolic disorders. His lab has made major advances in uncovering stress-signaling mechanisms in the pathogenesis of heart failure, and revealed functional importance amino acids catabolism in heart failure and metabolic disorders. In addition, his lab reported novel regulatory mechanisms in cardiac transcriptome reprogramming involving RNA splicing regulation and non-coding RNA mediated epigenetic modulation. Dr. Wang received an Established Investigator Award from American Heart Association in 2005. He was awarded the title of Chang-Jiang Scholar from Minister of Education of China in 2009, and Chinese National Expert for "Thousand Talent Plan".



Jinghai Chen

Professor Second Affiliated Hospital, Zhejiang University School of Medicine Institute of Translational Medicine, Zhejiang University

Dr. Chen's research is focused on noncoding RNA regulation of cardiac remodeling and regeneration during cardiac development and diseases. Most recently, he identified a microRNA cluster, miR-17-92, is a key regulator of cardiomyocyte proliferation in embryonic, postnatal, and adult heart. He has been further working on the mechanism of individual member of miR-17-92 cluster in cardiac regeneration and applying RNA therapy to cure ischemia heart disease and to prevent heart failure. His interested areas also include long noncoding RNA regulation in cardiac remodeling and regeneration. Dr. Chen is currently an associate editor of BMC cell biology. He reviewed papers from more than 10 scientific journals, including JMCC, Theranostics, Stem Cells International. He has served as an Ad Hoc reviewer for National Natural Science Foundation of China.



Joseph C. Wu

Simon H. Stertzer Professor, Medicine Professor, Radiology Director, Stanford Cardiovascular Institure Stanford University

Dr. Wu is the Simon H. Stertzer Professor of Medicine (Cardiology) and Radiology, and the Director of the Stanford Cardiovascular Institute. He has published >300 manuscripts. His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic cardiovascular disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop "clinical trial in a dish" concept, and (iv) implement precision cardiovascular medicine for prevention and treatment of patients. His lab uses a combination of genomics, stem cells, cellular & molecular biology, physiological testing, and molecular imaging technologies to better understand molecular and pathophysiological processes.



Jian'an Wang

Professor and Chief Physician, Department of Cardiology Director, Heart Center President, Second Affiliated Hospital, Zhejiang University School of Medicine Vice President, Chinese Society of Cardiology

Dr. Wang is full of enthusiasm in medical practice, research and education to promote health management in the population. He advocates evidence-based medicine, and is experienced in interventional cardiology, covering from invasive imaging, coronary catheterization, transcatheter aortic valve replacement (TAVR) and percutaneous mitral valve clip. He is the co-Editor-in-Chief of Internal Medicine as the national textbook for medical students. He is honored as a Distinguished Expert of Zhejiang Province and is rewarded the National Bethune Medal for his contribution in medical service and education. He received many research grants, including the national 973 project as the principle investigator. He is one of the pioneers in China for cell therapy of cardiovascular diseases and won National Science & Technology Progress Award (second class) for his innovative work in cardiac repair post myocardial infarction.



Xinyang Hu

Associate Professor and Attending Physician, Department of Cardiology Second Affiliated Hospital, Zhejiang University School of Medicine

Dr. Hu is an attending physician of the second affiliated hospital of Zhejiang university school of medicine and associate professor of Zhejiang University. She focuses on stem cells therapy for heart failure. She did a lot of work about hypoxia-preconditioning of MSCs from basic research to pre-clinical study and clinical study. She has established the non-human primates model for the stem cell pre-clinical study. She carried out the first large study of stem cell therapy for myocardial infarction in nonhuman primates and provided evidence to mechanistically support the beneficial effects of hypoxia preconditioning stem cells on cardiac remodeling and function. She has authored 15 research papers as first author or corresponding author, such as Circulation Research, Stem Cells etc. She received AHA Travel Stipend Award in 2014 and Circulation Research Best Manuscript Award in 2016.



Thomas M. Vondriska

Professor, Anesthesiology, Medicine, Physiology UCLA David Geffen School of Medicine

Dr. Vondriska's lab investigates epigenomic mechanisms of cardiovascular disease. Their systems biology approach marshals genomic, epigenomic and proteomic discovery tools to examine animal models and human populations. Bioinformatics and network biology play important roles in our investigations of chromatin biology and cardiovascular health. He wants to discover the basic principles of chromatin biology as well as to understand the causes of cardiovascular disease--towards the goal of new therapies and cures.



Atsushi Nakano

Assistant Professor, Molecular, Cell, and Developmental Biology UCLA

Dr. Nakano's lab studies how the process during which stem cells give rise to all types of heart cells is regulated in each phase of embryonic heart development, what molecular processes make cardiac muscle cells unable to divide, and how the ability of cardiac cells to change and take on the characteristics of other cells factors in to cardiac development and disease. Another area of focus for Nakano is uncovering how embryonic heart formation can go awry, leading to congenital heart disease, which affects nearly one in 100 children born in the U.S. He discovered that high levels of glucose keep heart cells from maturing normally. He hopes this work will lead to a better understanding of heart formation, which could inform the development of novel regenerative treatments for heart disease.



Meixiang Xiang

Professor and Chief Physician, Department of Cardiology Deputy Director, Heart Center Second Affiliated Hospital, Zhejiang University School of Medicine

Dr. Xiang is full of enthusiasm in both clinical and basic cardiac researches. Her clinical specialties include: 1) Individualized treatment for patients with heart failure; 2) Emergency treatment of cardiovascular critical patients; 3) Implantable cardiac devices indications and techniques, e.g. CRTD implantation. Her research interests are mainly focused on: 1) basic and clinical translational research on cardiac remodeling and heart failure; 2) the mechanism of artery injury and aortic aneurysm formation. She received many research grants, including National Science & Technology Pillar Program during the 12th Five-year Plan Period, and National Natural Science Foundation of China as the principle investigator. She was honored as a Distinguished Scholar of Zhejiang University in 2016, and won the first place of Science and Technology Advancement Prize of Zhejiang Province in 2008 and 2013, respectively.



Wei Zhu

Associated Professor, Department of Cardiology Second Affiliated Hospital, Zhejiang University School of Medicine

Dr. Zhu is presently working in the Key Cardiovascular Research Lab, the Second Affiliated Hospital Zhejiang University School of Medicine, doing basic cardiovascular research. In the past few years, he has investigated the specific microRNA expression profile of mesenchymal stem cells and its reparative roles using a mouse myocardial infarction model. He is also interested in the physio- and pathophysiological roles of mitochondrial dynamics proteins in cardiac remodeling process in heart failure. He has published research works in peer reviewed journals such as Circulation Research and Stem Cells. Recently, he worked with the research team and explored how certain mitochondrial structure protein can modulate ROS generation to regulate molecular signaling, conferring the protection against stress. The research work has elucidated how a moderate ROS generation within from the mitochondria exerts biological effects, and helped understand the concept of ROS compartmentation. The research work has been published in PNAS 2017.



Reza Ardehali

Associate Professor, Cardiology, Molecular, Cellular and Integrative Physiology UCLA David Geffen School of Medicine

Dr. Reza Ardehali is a clinician-scientist who treats patients with advanced heart disease and studies the molecular processes involved in heart development and disease. His lab is studying the extent of heart muscle cell division during pre-natal and post-natal development; how cardiac progenitor cells residing in the heart respond to injury such as a heart attack; and the mechanisms behind cardiac fibrosis, the process of scar formation in the heart. His lab discovered several cell surface markers that signify a stem cell was able to generate the cells that make up heart muscle and vessels. This discovery marks a significant step forward in the quest to use stem cells to create transplantable cells for heart regeneration. His goal is to use stem cells to create the heart through a minimally invasive procedure, which could regenerate the heart by replacing scar tissue and restoring heart function.



Loren Field

Professor, Medicine, Pediatrics Indiana University School of Medicine

Dr. Loren Field, a Molecular biologist, is a Professor of Medicine, of Pediatrics at the Indiana University School of Medicine. He received his PhD at State University of New York at Buffalo and completed his postdoctoral fellowship at Roswell Park Memorial Institute, Buffalo, New York. Prior to his affiliation with Indiana University, Dr. Field was a Senior Staff Investigator at the Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Dr. Field and his IU colleagues were the first to show that relatively simple genetic modifications can induce mammalian heart cells to regenerate. His current research is focused on identify genes and molecules that promote heart muscle regeneration by coaxing healthy cells to proliferate. The success of this research would offer the potential for seriously ill patients whose tissue has been damaged by heart attack to "re-grow" their own hearts.



Arash Pezhouman

Assistant Project Scientist III UCLA David Geffen School of Medicine

Dr. Arash Pezhouman is an assistant project scientist in Dr. Ardehali's lab. He is investigating the fate of transplanted cells (hESCs) after delivery to the heart. Their focus is to determine whether the transplanted cells can mature and functionally integrate into the myocardial syncytium and beat in synchrony with the host heart with no risk of arrhythmogenicity. During his time in Dr. Ardehali's lab he has been able to optimize the differentiation protocols to obtain purified chamber-specific cardiomyocytes for safe and effective cell transplantation. As a physician, he wants to stay aligned with research progress and its impact on the understanding of disease pathophysiology and health care technologies, as they ultimately change the standard of care for patients.



James F. Martin

Professor Vivian L. Smith Chair, Regenerative Medicine Baylor College of Medicine

Dr. Martin is an internationally recognized developmental and regenerative biologist who has made fundamental contributions to our understanding of development, disease, and regeneration. He has authored more than 135 peer-reviewed papers in top journals such as Nature, Science, Cell, Developmental Cell, Plos Genetics, Development, and PNAS. His recent groundbreaking work on the Hippo pathway in heart size regulation is a landmark study that led to the insight that the Hippo pathway is an inhibitor of adult heart muscle regeneration. Dr. Martin's insights revealed new avenues for treatment of human heart failure.



Alireza Khademhosseini

Levi Knight Professor, Bioengineering, Radiology, Chemical and Biomolecular Engineering Director, Center for Minimally Invasive Therapeutics (C-MIT) UCLA

Ali Khademhosseini is the Levi Knight Professor of Bioengineering, Chemical Engineering and Radiology and the Founding Director of the Center for Minimally Invasive Therapeutics at University of California-Los Angeles (UCLA). He joined UCLA in Nov. 2017 from Harvard University where he was Professor of Medicine at Harvard Medical School (HMS), and a faculty at Harvard-MIT Health Sciences and Technology and the Wyss Institute. He is a leader in applying bioengineering solutions to precision medicine. His large and interdisciplinary group is interested in developing 'personalized' solutions that utilize micro- and nanoscale technologies to enable a range of therapies for organ failure, cardiovascular disease and cancer. In addition, his laboratory is a leader in utilizing 3D bioprinting to form vascularized tissues as well as to direct stem cell differentiation. He has also pioneered various high-performance biomaterials that can respond to each patient's needs.



Arjun Deb

Associate Professor, Cardiology; Molecular, Cell and Developmental Biology UCLA

Dr. Arjun Deb treats patients with advanced heart disease and studies the basic mechanisms that regulate wound healing in the heart and other organs. Through this research, he strives to develop innovative treatment methods for a wide range of common diseases that are associated with wounds not healing properly, such as diabetes, chronic kidney disease and heart attacks. Deb aims to reduce heart failure rates by developing new drugs that reduce scarring as well as cell therapies that utilize heart stem cells to generate new heart muscle cells instead of scar tissue.



Hong Yu

Professor, Department of Cardiology Second Affiliated Hospital, Zhejiang University School of Medicine

Dr. Yu came back to China from University of Miami in 2011 as a Qiushi Chair Professor in Zhejiang University, Hangzhou, and was selected into the Thousand Telents Plan in Zhejiang Province. He has worked in the field of cardiovascular biology for more than 20 years. He has published more than 80 peer reviewed papers. His research is focused on stem cell thearpy for cardiovascular diseases, and the effects of aging on the activity of stem cells and their rejuvenation. He has been working on how to improve the activities of stem cells for better efficacy of cell therapy to cure cardiovascular diseases. His interested areas include promoting angiogenesis using progenitor cells, rejuvenation of aged stem cells and prevention of vascular calcification using an agonist of growth hormon releasing hormon, the roles of GDF11 in cardiac progenitor cells and cardiomyocytes, and effects of exosomes on stem cells and endothelial cells.



Huangtian Yang

Principal Investigator and Head, Laboratory of Molecular Cardiology Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Vice President, ISHR-China Section & Shanghai Society for Cell Biology

Dr. Huangtian Yang is Principal Investigator, head of Laboratory of Molecular Cardiology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (CAS). She received MD degree from Yamagata University School of Medicine in 1994, served as an Instructor/associate professor in the Dept of Pharmacology in Nantong Medical College and Yamagata University School of Medicine, then moved to Gerontology Research Center, NIH/NIA in 1997, and took the current position since 2000. Her research interest is identifying novel targets and developing therapeutic strategies related to the prevention and treatment of ischemic heart diseases. Her current research is focused on (i) regulation of cardiac lineage commitment of pluripotent stem cells and their applications in myocardial repair; (ii) mechanisms and application potentials of intermittent hypoxic adaptation-, natural compounds-, and endogenous factors in cardioprotection and cardiac regeneration; and (iii) Ca2+ regulation in cardiogenesis and cardioprotection.



Zhao Wang

Assistant Professor Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center

Dr. Zhao Wang is Assistant Professor in the Cardiology Division of University of Texas Southwestern Medical Center. He received PhD degree from Dr. Philipp Scherer lab in Albert Einstein College of Medicine, focusing on obesity and diabetes. Dr. Wang did postdoctoral training in Dr. Joseph Hill's lab for cardiac disease at University of Texas Southwestern Medical Center. Dr. Wang's lab now works on the mechanisms of cardiac remodeling under hypertension and myocardial infarction, heart failure, diabetic cardiomyopathy and the metabolic syndrome. Dr. Wang has published more than 60 peer-reviewed papers that are widely cited. Dr. Wang's work is supported by grants from National Institute of Health, American Heart Association, and American Diabetes Association.



Xiyong Yu

Dean, Guangzhou Medical University School of Pharmaceutical Sciences President, Guangdong EpiPharm Institutes of Biomedicine Chairman, Chinese Association of pathophysiology Cardiovascular Committee Vice President, International Society for Heart Research (ISHR)-Chinese Section Co-honorary Chairman, ISHR China Committee of Translational Medicine Chairman, Chinese Pharmacology Society Pharmacoepigenetic Committee

Dr. Yu Yu engages in research field of molecular cardiology and clinical pharmacology. His main research interests are the epigenetic regulation of stem cells on cardiac remodeling. There were more than 400 papers published in the domestic and abroad (>130 SCI papers) academic journals, 9 books issued, and 11 National (or PCT) invention patents gotten. He has undertaken more than 20 research projects from the National 973 programs, National Natural Science Foundation (NSFC), the Provincial Natural Science Fund and other scientific and technological programs. Professor Yu won 5 Medical and Health Progress Awards, and 3 Science and Technology Awards from Guangdong Provincial Government. He has also been awarded as one of the academic and technology leaders of medical science and education project in Guangdong Province, the Chinese Industry-University-Institute Integration Innovation Award, the Ten Outstanding Young Persons in Guangdong Province Nomination Award, the State Department experts in special government allowances, the Guangdong provincial authorities forefront positions.



Bin Zhou

Professor, Chinese Academy of Sciences

Dr. Bin Zhou obtained his Bachelor degree from Zhejiang University School of Medicine in 2002, and received Ph.D. degree from Chinese Academy of Medical Sciences and Peking Union Medical College (PUMC) in 2006. From 2006-2010, Dr. Zhou had postdoctoral training with Dr. William Pu at Boston Children's Hospital and Harvard Medical School. In 2010, Dr. Zhou became professor and group leader in Chinese Academy of Science. The major goal of his lab is to understand the cellular and molecular mechanisms of cardiovascular development, diseases and regeneration. His lab develops more precise genetic lineage tracing and gene targeting technology to better understand the origin and fate of cardiovascular cells in development, diseases and tissue regeneration.



Qing Jing

Professor and Principal Investigator, Lab of RNA and Molecular Medicine Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences

Dr. Jing focuses on understanding the mechanisms of cardiovascular development, disease and repair. His Group established in vivo and in vitro systems for exploring the cellular and molecular mechanisms of vascular development and screening drugs to produce sufficient functional cardiomyocytes for cardiac regeneration. He is elected as Fellow of American Heart Association since 2012. He has published 48 articles in international SCI journals, including Eur Heart J, Circ Res, J Cell Biol, ATVB and Cell. His articles have been cited more than 4000 times, one (Eur Heart J, 2010) has been cited more than 990 times (Google Scholar).



Peng Shi

Principal Investigator, Zhejiang University

Dr. Peng Shi obtained her Ph.D from University of Texas Health in San Antonio in 2007, and then received post-doc training in University of Florida 2007-2011. Dr. Shi took an Assistant Professor position in the Department Neurology in Cedars Sinai Medical Center in Los Angeles USA 2011-2016. Since April 2016, Dr. Shi setup her research program in the Institute of Translational Medicine, Zhejiang University as Principal Investigator. Her research is focus on the microglia-mediated neuroinflammation on autonomic regulation in cardiovascular and neurodegenerative diseases.



Luyang Yu

Professor, College of Life Sciences Zhejiang Univerisity

Dr. Luyang Yu received his B.S. degree in biological science and technology from Zhejiang University in 2000 and his Ph.D. degree in cell biology at Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences in 2005. Afterwards he performed 4-year post-doctoral training and then worked as associate research scientist in Vascular Biology & Therapeutics program and Department of Pathology, Yale School of Medicine. In 2013, he was recruited back to College of Life Sciences, Zhejiang University as professor and then appointed as associated dean in 2016. Dr. Yu is a member of NAVBO, AHA, ASIP, CAPS and CSMB. Dr. Yu's lab has extensively employed biochemical, cell biological, histological and mouse genetic approaches to define the role of posttranslational modifications in mediating vascular development and vascular diseases. Dr. Yu has been the recipient of many awards, including AHA Scientist Development Award, A. D. Sobel - ASIP Education Fund Scholar Award and NSFC Excellent Young Scientist.



Aijun Sun

Professor, Zhongshan Hospital, Fudan University, Shanghai. Vice Director, Shanghai Clinical Center for Cardiovascular Diseases Vice President, Youth Committee of Chinese Society of Cardiology

Dr. Sun acquired Doctor Degree in Shanghai Second Medical University in 2002, worked as visiting scholar in Essen University, Germany in 2003, and University of Texas (Houston), US in 2014. Dr. Aijun Sun has been engaged in exploring the molecular mechanisms and translational study on HF in the past 15 years. She clarified the novel mechanisms by which ALDH2 could slow down HF progression via maintaining the metabolic homeostasis and subsequent enhancement of myocardial protection and improvement of revascularization. She also proposed a novel concept to increase the efficiency of stem cell transplantation by improving its energy metabolic patternt. She is in charge of 12 national research grants, and has published 20 articles in famous periodicals including Circulation, Nat Commun in the last 5 years.



Jun Jiang

Chief Physician and Deputy Director, Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine

Dr. Jiang is the deputy director of department of Cardiology, the Second Affiliated Hospital, Zhejiang University School of Medicine Dr. Jiang received his MD. degree at Zhejiang Medical University in China and was trained in clinical cardiology at Sir Run Run Shaw Hospital, interventional cardiology at Second Affiliated Hospital, Zhejiang University School of Medicine, and basic research in Medical University of South Carolina in 2005. He is currently the Young member of the Chinese society of Cardiology. He is full of enthusiasm in medical practice, research and education to promote health management in the population, with special interests in imaging and physiology optimized percutaneous coronary intervention (PCI), complex lesion (CTO and left main) PCI, and solutions for cardiac rupture after acute myocardial infarction.



Xiaojie Xie

Chief Physician, Department of Cardiology Second Affiliated Hospital, Zhejiang University School of Medicine

Dr. Xiaojie Xie is the director of education department of the Second Affiliated Hospital, Zhejiang University School of Medicine. Dr. Xie received her MD. & PhD. degree at Zhejiang University in China and was trained in cardiovascular research at Kentucky University (United States) in 2006, and stem cell clinical trials in Hospital Universitario Reina Sofia (Spain) in 2011. She devotes herself to American Heart Association training program as an instructor of Basic Life Support, Advanced Cardiovascular Life Support, and Experienced Provider. Dr. Xie is currently the committee member of Chinese Society of Cardiology, as well as the president assistant of Guizhou University. She is full of enthusiasm in medical practice, education and research to promote health care and management in the population. She is honored as an Excellent Teacher of China Resident Standardized Training for her great contributions to medical education. She has been worked in National Natural Science Funds Commission in 2011 and received many research grants as the principle investigator. She is also experienced in clinical trials of cardiovascular disease. Her research focuses on the pathogenesis and molecular targets of abdominal aortic aneurysm and atherosclerosis.



Ping Liang

Professor, Institute of Translational Medicine, School of Medicine Zhejiang University |

Dr. Ping Liang got his MD at China Medical University in 2005 and obtained his PhD at Peking University in 2010. He then did his postdoc with Dr. Joe Wu at Stanford during 2011-2014. He joined Institute of Translational Medicine at Zhejiang University and became a full professor in 2014. Ping's researches are focusing on understanding cellular and molecular mechanisms of channelopathies and cardiomyopathies using iPSCs, and his work have been published on Cell Stem Cell, Circulation, JACC, JCMM, Stem Cell Research & Therapy, JBC and Biophysical Journal.



Weinian Shou

Professor, Pediatrics, Biochemistry & Mo Indiana University School of Medicine

Dr. Weinian Shou is Professor of Pediatrics, Biochemistry & Mol. Biol., Medical & Mol. Genetics, Pharmacology & Toxicology in Indiana University School of Medicine. He got his Ph.D. at Shanghai Institute of Cell Biology, CAS. He had the postdoc training at M.D. Anderson Cancer Center and Baylor College of Medicine from 1991 to 1997. The major research in his lab focus undertaken in his lab is to determine the molecular signaling pathways involved in the ventricular wall growth, maturation, regeneration and function in normal and various disease conditions using mouse genetic manipulation.



Feng Gao

Professor and Director, the Laboratory of Aerospace Cardiovascular Protection Fourth Military Medical University

Feng Gao is Professor and Director of the Laboratory of Aerospace Cardiovascular Protection at Fourth Military Medical University, China. Dr. Gao has been engaged in teaching of physiology and research in cardiovascular physiology with focus on cardiovascular protection. His lab has found that insulin-induced "survival" signaling and resultant cardioprotection may represent a novel strategy for the prevention of insulin resistance and diabetic cardiovascular impairment. Currently, his team is actively exploring the role of mitochondria in exercise-induced cardiovascular protection. Their findings have been published in Circulation, JACC, Crit Care Med, Hypertension, Cardiovasc Res and Am J Physiol. His research is currently funded by the National Natural Science Foundation of China and Key Project of Basic Science sponsored by Ministry of Science and Technology of China. Dr. Gao has served as Editorial Board Member of Cardiovasc Res, Apoptosis, and Am J Physiol Heart Circ Physiol, and Associate Editor of Life Sciences, Executive Associate-Editor of Acta Physiologica Sinica.



Chunyu Zeng

Dean, Hospital of Cardiology; Chairman, Department of Cardiology, Chairman, Chongqing Institute of Cardiology Chairman, Chongqing Key Laboratory for Hypertension Research Professor in Cardiology, Daping Hospital, The Third Military Medical University,

Dr. Zeng is expert on percutaneous coronary artery intervention in clinical work. For research work, he is devoted to the basic and clinical research on hypertension and regeneration of adult cardiomyocyte. His interesting research includes role of dopamine receptor, GRK4 in hypertension; dialogue between enviroment factor and gene in hypertension; adverse environment in utero and hypertension in offspring; nong-coding RNAs and cardiovascular disease; stem cells and repair of ischemia-injury heart; protection of ischemia-reperfusion injury; optimization of anti-hypertensive setup. He published more than 130 original papers in the English journals, including Circulation, Circ Res, Sci Transl Med, Nat Commun, Hypertension and Kidney Int; who was invited to write more than ten review manuscripts and commentary for Hypertension and other journals. Some of those papers were taken as cover pages, with commentary, included in F1000, and highlighted by journal in the cover page. Dr. Zeng's findings have been taken as top ten influential events and top ten major progresses in cardiovascular area in China, recommended as important milestones by journal of Nat Rev Cardiol.

GUEST INTRODUCTION

Professor, Pediatrics, Biochemistry & Mol. Biol., Medical & Mol. Genetics, Pharmacology & Toxicology

嘉宾介绍 GUEST INTRODUCTION



Hao Zhang

Deputy Director, Department of Cardiac Surgery Chief Surgeon, Center for Pediatric Cardiac Surgery Director, Key Laboratory of Cardiac Reg. Med, the Ministry of Health Secretary General, National Council for Congenital Heart Disease Professor, Peking Union Medical Science Fuwai Hospital & National Center for Cardiovascular Diseases Chinese Academy of Medical Science

Dr. Zhang has a busy clinical practice for the surgical treatment of congenital heart diseases. His clinical research focused on the development of new cardioprotection approach (EHJ 2012) and outcome research for the children after heart surgery (Lancet Child & Adolescence Health 2018). He also has strong interesting for the stem cell-based therapy for heart disease (Nat Communication 2018, Circ 2010, J Mol Cell Cardiol 2013 Circ 2010). He is the director of key laboratory of cardiac regenerative medicine, the Ministry of Health, China. He was awarded the National High Level Talents Special Support Plan in 2017 and National Science Fund for Distinguished Young Scholars in 2015.



Xianbao Liu

Chief Physician and Deputy Director, Department of Cardiology Second Affiliated Hospital Zhejiang University School of Medicine

Dr. Liu is one of the key members in Prof. Jian'an Wang's clinical and translational research team. He helps prof. Wang to organize transcatheter aortic valve replacement (TAVR) program, that is one of the leading TAVR centers in China focusing on new device R&D and technical innovation in bicuspid aortic stenosis. He is interested in the translational research of calcified aortic stenosis and functional improvement of aged stem cell therapy in myocardial infarction. As principal investigator, he has 4 national grants including 1 grant from national 863 program and 3 grants from national natural science foundation of China. Publications include over 40 articles in peer-reviewed international medical journals such as J Heart Lung Transplant., Cell Death Dis. and Int J Cardiol. etc.